Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study

Avivit Cahn, Itamar Raz, Marc Bonaca, Ofri Mosenzon, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, John P.H. Wilding, Deepak L. Bhatt, Darren K. McGuire, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Gyorgy Jermendy, Samy Hadjadj, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott, Lawrence A. Leiter

Research output: Contribution to journalArticle

Abstract

Aims: To evaluate comprehensively the safety of dapagliflozin in patients with type 2 diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium-glucose co-transporter-2 inhibitor class. Methods: In the Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) study, 17 160 patients with T2DM were randomized to dapagliflozin or placebo and followed for a median of 4.2 years. Safety was evaluated in 17 143 patients receiving at least one dose of study drug. Results: Acute kidney injury occurred less frequently with dapagliflozin, and adverse events suggestive of volume depletion were balanced between treatment groups, both irrespective of baseline estimated glomerular filtration rate, blood pressure, diuretic or loop diuretic use (interaction P values >0.05). Fractures and malignancies were balanced between the groups, irrespective of sex, diabetes duration or smoking (interaction P values >0.05) and fewer cases of bladder cancer occurred in the dapagliflozin versus the placebo group. Diabetic ketoacidosis was very rare, but more frequent with dapagliflozin versus placebo (27 vs. 12 patients with events; P = 0.02), yet signs, symptoms and contributing factors were similar in the two groups. Major hypoglycaemia occurred less frequently with dapagliflozin versus placebo, regardless of baseline use of either insulin or sulphonylureas (interaction P values >0.05). There were more adverse events of genital infections leading to discontinuation of study drug in the dapagliflozin versus the placebo group, but serious genital infections were few and balanced between treatment groups. Urinary tract infections, acute pyelonephritis and urosepsis were also balanced between treatment groups. Conclusions: Dapagliflozin was well tolerated. The long duration and large number of patient-years in DECLARE-TIMI 58 comprehensively addressed previous safety questions, confirming the robust safety profile of dapagliflozin.

Original languageEnglish (US)
JournalDiabetes, Obesity and Metabolism
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • SGLT2 inhibitor
  • acute kidney injury
  • dapagliflozin
  • diabetic ketoacidosis
  • fractures
  • genital infections
  • hypoglycaemia
  • malignancy
  • safety
  • urinary tract infections
  • volume depletion

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study'. Together they form a unique fingerprint.

  • Cite this

    Cahn, A., Raz, I., Bonaca, M., Mosenzon, O., Murphy, S. A., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Bhatt, D. L., McGuire, D. K., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Jermendy, G., Hadjadj, S., Langkilde, A. M., Sabatine, M. S., Wiviott, S. D., & Leiter, L. A. (Accepted/In press). Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14041